ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOUNDS

Abstract: The present invention relates to antimicrobial and anti-inflammatory compounds. The invention is characterized by the use of a hydroxy acid containing at least 4 carbons and having either a branched or linear carbon chain, or of a mixture of said acids, in the manufacture of a preparation having antimicrobial and/or proteinase-activity-inhibiting efficacy.

Description: Antimicrobial and anti-inflammatory compounds The present invention relates to the use of a hydroxy acid or a product containing the same as defined in the annexed claims and a product made thereof. According to the invention, the use of hydroxy acids is based on their inhibitory and bacteri¬ cidal efficacy on micro-organisms and proteinases, particularly the inhibition of matrix metalloproteinases. Matrix metalloproteinases are proteolytic enzymes which hydrolyze the proteins of the basement membrane of connective tissue and inflammation transmitter substances. The state of the art is described in, e.g., publication Nutrition and Metabolism 23 (3), pp. 227-234 (1979), according to which two alpha-hydroxy acids, namely, alpha-hydroxy-isovaleric acid (d,l-2-hydroxy-3-methyl butyric acid) and alpha- hydroxy-isocaproic acid (d, l-2-hydroxy-4-methyl valeric acid) are isolated from a solution. The solution is obtained from protein-rich animal-based waste through Lactobacillus plantarum fermentation. The isolation of these acids was initiated by the discovery that such a fermentation solution exhibits growth- inhibiting efficacy on two micro-organisms, namely, Escherichia coli and Trichophyion sp. In the present invention it has been found that these compounds are inhibitory to a large spectrum of micro-organisms. Lactic acid bacteria and lactic acid are widely used to modify and preserve organic material such as nutrients and animal feed. Lactic acid is also used in the treatment of skin diseases. According to US Pat. No. 5,389,679, lactic acid can be used in the treatment of lesions of the mouth, especially aphthosis. The etiology of these lesions of the mucous membrane is uncertain. Reference is herein made to Streptococcus sanguis bacterium, which may be a partial cause to the onset of this disease among other factors. The antimicrobial efficacy of lactic acid may be exerted via acidity alone, provided that any significant antimicrobial effect in the healing of aphthosis exists at all. Matrix metalloproteinases can also be found in these ulcer¬ ations. On this basis it is plausible to assume the inhibition of these proteinases to have an effect in the treatment of oral cavity lesions irrespective of whether a microbial infection is an essential cause in the occurrence of the lesions or not. US Pat. No. 4,772,592 discloses improved preparations for the local treatment of acne. The active compounds described therein are esters formed by lactic acid with C j - C 4 alcohols. The active compounds are assumed to comprise free lactic acid and alcohol that are formed by lipases of bacterial origin after the esters have resorbed through the epidermis of the skin. US Pat. No. 4,380,549 describes a large number of organic acids, their salts and other derivatives suited for the treatment of "dry skin". Acids occurring in the nature and made through synthetic pathways can be used for said purpose in different formulations. The pH of such formulations has been in the range 2.7 - 5.7. In cited US Pat. No. 4,380,549, the possible antimicrobial efficacy or inhibi¬ tion of proteolytic enzymes exhibited by said compounds in the treatment of the "dry skin" syndrome is not discussed nor indicated in any form at all. US Pat. No. 4,363,815 describes the use of alpha-hydroxy acids and alpha-type keto acids in conditions characterized by disturbed keratinization. Alpha hydroxy acids can be used for local treatment in these disorders. The effective compounds include all hydroxy and keto analogues of amino acids irrespective of whether the corresponding amino acids occur in the proteins or not. According to the present invention, alpha-hydroxy acids can be used for improving the anti-inflammatory efficacy of corticosteroids and as a stabilizer of dithranol in formulations suited for local treatment. The antimicrobial efficacy of these acids and their inhibitory efficacy on matrix metalloproteinases have not been taken into account as a potential mechanism of action. The present invention describes a novel use of alpha-hydroxy acids acting through the general antimicrobial efficacy of these compounds and via their inhibitory efficacy on matrix metalloproteinases. The characterizing specifications of the invention are disclosed in the annexed claims. Their efficacy on microbial infec- tions and ingress of pathogenic microbes into tissues is divided into two steps: growth of organisms is inhibited by alpha-hydroxy acids, and inhibition of matrix metalloproteinases in the host cells prevents the escalation of the inflammation. The invention offers significant benefits. The hydroxy acids, or mixtures thereof, utilized in accordance with the invention can be either synthesized chemically or produced biotechnically into, e.g., a fer¬ mentation solution containing the bacterium. An essential requirement herein is that the acid contains at least 4 carbon atoms and/or a compound or compounds incoφorating a branched carbon chain or an aromatic or other suitable substi¬ tuent. Particularly advantageous in this aspect are 2-hydroxy-3-methyl butyric acid, 2-hydroxy-4-methyl valeric acid or a mixture thereof. The invention also concerns the use alpha-hydroxy acids in the manufacture of pharmaceutical products. Matrix metalloproteinases (MMP) are proteolytic enzymes that are produced by human and mammal cells to provide for the lysis of the external connective tissue and basement membrane of the cell when required (cf. Woessner F. Jr. , Ann. N.Y. Acad. Sci. 732: 11-21 , 1994). MMP enzymes are capable of disintegrating almost all proteins of the connective tissue external to the cell and the cell basement membrane as well as, during the acute phase of a disease, certain serine proteinase inhibitors of serum (that is, inhibitors and serpines such as alpha- 1- antitrypsin) and inflammation transmitter substances (e.g., the alpha factor of tumor necrosis) (cf. Krane S.M. , Ann. N.Y. Acad. Sci. 732: 11-21 , 1994). While the number of members in the MMP enzyme family today includes 14 different members produced by different genes, obviously new members of the MMP enzyme family will be identified in the long run (cf. Matrisian L.M.. Ann. N.Y. Acad. Sci. 732: 42-50, 1994). In many human and mammal diseases (e.g., rheumatic, gingival, cancer, blood vessel, gastrointestinal, ear, eye, skin diseases and painful recurring ulcerations of the oral cavity), the increased production and activation of MMP enzymes in different types of cells which are either infected or surrounding/adjacent to such human and mammal inflamed lesions exceed the concentrations and inhibitory efficacy of the inhibitor proteins (alpha-2-macroglobulin) and the tissue inhibitors (TIMP molecules) of MMP enzymes produced by the organism itself. This often causes a local and/or systemic tissue damage or lesions typical of the disease (cf . Sorsa et al., Ann. N.Y. Acad. Sci. 732: 112-131, 1994, Woessner J. Fr. , Ann. N.Y. Acad. Sci. 732: 11-21, 1994, Hayrinen-Immonen et al. , Int. J. Oral. Maxillfac. Surg. 22: 46-49, 1993, Hayrinen-Immonen et al. , J. Oral. Pathol. Med. 23: 269-272, 1994), whereby the pathological changes are characterized by disintegration and damage of the connective tissue and basement membrane structure and adhesion as well as diseases and lesions of skin, gingival tissue, mucosa parts of mouth and the intestinal tract, cornea, cartilaginous and bone tissues. Simultaneously, the activities of serine proteinases (e.g., cathepsin-G) are elevated in the different diseases of humans and mammals (cf. Weiss, S.J. , N. Engl. J. Med. 320: 365-376, 1989, Tervahartiala et al. , J. Clin. Periodontol. 23: 68-75, 1996). Microbes capable of producing proteinases in conjunction with parodontites include: - Bacteroides forsythus - Porphyromonas gingivalis - Prevotella intermedia - Fusobacterium nucleatum - Treponema denticola - Peptostreptococcus micros - Actinobacillus actinomycetemcomitans - Campylobacter rectus. The function of alpha-hydroxy acids according to the invention is to lower or prevent the occurrence of pathologically elevated activities and concentrations of matrix metalloproteinases and serine proteinases (cathepsin G) so that normal cellular activities and concentrations of these proteinases are maintained in the tissues of human and mammal organisms during diseases which usually involve elevated activities and concentrations of said enzymes. Alpha-hydroxy acids are suited for both treatment of infections in humans and mammals as well as eradication of multiresistant microbes from their carriers. The invention concerns the use of alpha-hydroxy acids in all pharmaceutically acceptable forms including tablets, capsules, powders, granules, syrups, elixirs and rectal suppositories. The tablets may be coated or uncoated. Besides the antimicrobially active component, the oral preparations and rectal suppositories may incoφorate other pharma- ceutically acceptable constituents. The invention further concerns locally applied preparations, ointments, solutions, dispersions, tinctures, drops and rectal suppositories that are used for both curative or preventive treatment of infections affecting skin, mucous tissues, ophthalmological, gynecological, otological, oral and other sites of infections as well as eradication of pathogenic and multiresistant microbes from their carriers. Examples on the use of alpha-hydroxy acids for prevention of microbial infections in epithelic tissues were carried out using two acids: d,l-2-hydroxy-3-methyl butyric acid and d, l-2-hydroxy-4-methyl valeric acid. These acids are physiologi- cally acceptable, since their complete catabolism in organic tissues has been verified by means of thorough investigations into their enzymatic reactions. According to current knowledge, their use must be limited to the skin, the oral cavity and the alimentary tract only. At the administration level used according to the invention, no systemic side-effects are to be expected. Inasmuch as is known from these acids, their resoφtion from the intestine takes place passively. Therefore, their retention time in the intestine becomes long, which enhances the antimicrobial efficacy exerted by the acids in the gastrointestinal tract. As the d,l-2-hydroxy-3-methyl butyric acid and the d,l-2-hydroxy-4-methyl 5 valeric acid are soluble in both water and lipid-dissolving fluids, they will be distributed between the aqueous and lipid phases. Both of them are dissociable organic acids with pK a 3.80. Hence, the antimicrobially active form of these acids is the free acid, not the anion. Further, their antimicrobial efficacy is dependent on the pH. At pH 3.8, these acids are half-neutralized, whereby the i o buffering capacity of their solutions is at a maximum. Accordingly, the locally applied preparations formulated for prevention of infections are advantageously buffered to pH 3.8. In the following, the invention will be described in greater detail with die help of 15 the following examples and with reference to annexed drawings in which Figure 1 is a plot of the growth inhibition of E. coli and S. aureus by HMV (d,l-2-hydroxy-4-methyl valeric acid); 20 Figure 2 is a plot of the inhibition of GCF (gingival crevicular fluid) collagenase activity by HMV (d,l-2-hydroxy-4-methyl valeric acid) and HMB (d,l-2- hydroxy-3-methyl butyric acid) with and without APMA (aminophenyl mercuric acetate). 25 Figure 3 is a plot of the dose-dependent inhibition of the catalytic activity of human gingival crevicular liquid collagenase (MMP-8 inhibition) by means of alpha-hydroxy acids; Figure 4 is a plot of the reduction/inhibition of the catalytic activity of human 30 fibroblast gelatinase A (72 kD type IV collagenase MMP-2) and of human neutrophil gelatinase B (92 kD type IV collagenase MMP-9) by alpha-hydroxy - isocaproic acid; Figure 5 is a plot of the reduction/inhibition of the catalytic activity of human fibroblast gelatinase A (MMP-2) by alpha-hydroxy-isovaleric acid; Figure 6 is a plot of the inhibition of the catalytic activity of cathepsin-G isolated from human neutrophils; and Figure 7 is a plot of the inhibition of the catalytic activity of cathepsin-G isolated from human neutrophils. The following examples describe the effects of these alpha-hydroxy acids and their use in the prevention of infections. As the examples are given only to elucidate the invention, the applications of the invention are not limited thereto, but rather, the materials and uses described in the examples can be varied for different puφoses within the scope and spirit of the invention disclosed in the annexed claims. Abbreviations -used in the examples: HMV = d,l-2-hydroxy-4-methyl valeric acid HMB = d,l-2-hydroxy-3-methyl butyric acid MMP = matrix metalloproteinase, different types identified with a code number GCF = gingival crevicular fluid APMA = aminophenyl mercuric acetate. Example 1 The antimicrobial efficacy of d, l-2-hydroxy-3-methyl butyric acid and d,l-2- hydroxy-4-methyl valeric acid was tested in vitro. The concentration of these compounds were adjusted to 4 mg/ml of typical culture medium solution of for each microbe listed below. The pH of the culture medium solutions was adjusted at pH 5.2. Growth inhibition was detected for the following microbes: Trichophyton sp. Escherichia coli Staphylococcus aureus Salmonella typhimurium Salmonella typhi 643 W Streptococcus pyogenes Streptococcus mutans Klebsiella pneumoniae Helicobacter pylori Staphylococcus capitis MCS A 11 ATCC 27 482 Staphylococcus warneri RM 130 ATCC 27837 Staphylococcus lactis 15306 Staphylococcus muscae ARCC 121162 Staphylococcus xylosus KL 162 Staphylococcus simulans MK 148 ATCC 27848 Staphylococcus epidermis AW 269 Staphylococcus haemolyticus SM 131 Staphylococcus cohnii GH 137 Staphylococcus cit reus 413 Manchester Staphylococcus hominis KL 243 ATCC 27846 Staphylococcus saprophyticus TW 11 Staphylococcus epidermis 128 Lausanne Example 2 A mixture of d, l-2-hydroxy-4-methyl valeric acid and its sodium salt was prepared in mole ratio 1 : 1. The mixture was homogenized and sifted through a 200-mesh sieve. The powder thus obtained was rubbed on irritated skin areas of patients infected by Trichophyton, twice a day, in the morning and in the evening. The Trichophyton infection was healed in two weeks. Example 3 Growth medium: the bacteria were grown on trypticase-soya-meat extract medium (BBL) having its pH adjusted acid (at pH 5.5). Into this medium were added increasing amounts of d,l-2-hydroxy-4-methyl valeric acid (HMV) and adjusted again at pH 5.5. Bacterial strains: the bacteria used in the example were strains Staphylo¬ coccus aureus ATCC 25923 and Escherichia coli ATCC 23682 obtained from American Type Culture Collection. Measurement of antibacterial activity: bacterial colonies grown on blood agar dishes at 37 °C were suspended in sterile salt solution (0.9 % NaCl) and a further dilution of this suspension (into sterile salt solution) was used as a bacterial graft for inoculating growth medium aliquots of 200 μl pipetted into wells of microtiter plates (the size of the graft was about 10 5 colony-forming units (CFU) per milli¬ liter). The plates were next incubated at 37 °C for 24 h (S. aureus) or 48 h (E. coli). Subsequently, the bacterial growth was determined by measuring the absorbance of each well at A 405 nm wavelength using Titertek Multiscan spec- trometer (vendor Labsystems Oy, Helsinki, Finland). One well of the microtiter plate containing noninoculated culmre medium only was used as the zero refer¬ ence of the spectrometer. Results: Fig. 1 is a plot of the test results. The growth of Staphylococcus aureus and Escherichia coli is plotted in relative units in trypticase-soya- meat extract culmre medium (at pH 5.5) containing l-2-hydroxy-4-methyl valeric acid. The inhibitory effect of d,l-2-hydroxy-4-methyl valeric acid on the growth of both S. aureus and E. coli is seen at an HMV level of 1 mg/ml culture medium. Example 4 Preparations and buffer solutions: preparation A (0.625 % HMV) contained one part of 2.5-percent d,l-2-hydroxy-4-methyl valeric acid (HMV) ointment (pH 3.9) and three parts of sterile distilled water. Preparation B (control preparation) contained one part of acid ointment (pH 3.8) and three parts of distilled water. The phosphate-buffered sterile salt solution (pH 7.2, PBS) contained 0.9 % NaCl and 0.01 M potassium phosphate buffer solution. Bacterial strains: the bacterial strains in the test were Streptococcus pyogenes ATCC 19615, Staphylococcus aureus ATCC 25923, Pseudo¬ monas aeruginosa ATCC 27853 and Escherichia coli ATCC 23682 obtained from American Type Culmre Collection. Stenotrophomonas (Xanthomonas) maltophilia KY 3728, Acinetobacter sp. KY 109 and Propionibacterium acnes KY 16409 were clinical isolations obtained from the strain collection of Helsinki University, Unit of Diagnostic Bacteriology (Helsinki, Finland). Assay of antibacterial activity: bacterial colonies, which were grown on blood agar dishes at 37 °C under anaerobic conditions (P. acnes), in a candle jar (Str. pyogenes) or aerobically (other strains), were suspended in sterile salt solution (0.9 % NaCl) and a further dilution of this suspension (into sterile salt solution) was used as a bacterial graft for inoculating 1 ml aliquots of prepara¬ tions A and B (the size of the graft was about 10 5 colony-forming units (CFU) per milliliter). The inoculated aliquots of the preparations were next incubated at 37 °C for 18 h. Subsequently, the amounts of surviving bacteria were determined by first transferring a 5μl sample into 500 μl of PBS solution, then diluting this solution into PBS in increasing powers n of ten per ml of PBS and finally inoculating blood agar dishes with these successive series of dilutions. The colonies were allowed to grow at 37 °C for 3 days (P. acnes) or 24 h (other strains) under the growth conditions described above. Results: Table 1 below shows the test results. Preparation A (0.625 % HMV) was able to suppress the viability of the following bacterial strains by a factor of ≥ 100: Streptococcus pyogenes ATCC 19615, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa ATCC 27853, Esche- richia coli ATCC 23682, Stenotrophomonas maltophilia KY 3728 and Acinetobacter sp. KY 109. The viability of Propionibacterium acnes KY 16409 strain was suppressed by a factor of 10. Table 1. Amount of viable bacterial cells (expressed as colony-forming units per milliliter, CFU/ml), after the bacteria were treated by at 37 °C for 18 h using preparation A (2.5 % HMV ointment, pH 3.9, diluted with water in ratio 1 :3 v/v) and preparation B (control ointment, pH 3.8, diluted with water in ratio 1 :3 v/v). The amount of bacterial graft was 10 5 CFU/ml. Bacterium Preparation A Preparation B (HMV) (control) Streptococcus pyogenes ATCC 19615 < 10 3 < 10 3 Staphylococcus aureus ATCC 25923 < 10 3 800 x 10 3 Pseudomonas aeruginosa ATCC 27853 < 10 3 2500 x 10 3 Escherichia coli ATCC 23682 < 10 3 3000 x 10 3 Stenotrophomonas (Xanthomonas) < 10 3 2 x 10 3 maltophilia 3728 Acinetobacter sp. 109 < 10 3 2000 x 10 3 Propionibacterium acnes KY 16409 4 x 10 3 < 10 3 Example 5 This example was carried out to test the dose-dependent inhibition of the catalytic activity of human neutrophil collagenase (MMP-8 inhibition) by means of alpha¬ hydroxy acids. In the test, human neutrophil collagenase (MMP-8, 500 ng, both without and with activation with 1 mM aminophenyl mercuric acetate; cf. Sorsa et al. Ann. N.Y. Acad. Sci. 732: 112-131 , 1994) was pretreated (at 37 °C for 1 h) with a buffer solution (using TNC buffer solution containing 50 mM Tris- HCl, 0.15 M NaCl, 1 mM CaCl 2 , pH 7.8) and with 1-100 μg/μl alpha-hydroxy- isocaproic acid (d, l-2-hydroxy-4-methyl valeric acid, titrated at pH 7.8) and with alpha-hydroxy isovaleric acid (d,l-2-hydroxy-3-methyl butyric acid, titrated at pH 7.8) and subsequently incubated in TNC buffer solution with 1.5 μM soluble native type I collagen at ambient temperamre (22 °C) for 12 h. Next, the samples were boiled at 100 °C for 5 min in Laemmli buffer solution and analyzed using 8-10 % sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis (cf. Sorsa et al. , Ann. N.Y. Acad. Sci. 732: 112-131 , 1994). The SDS-PAGE gels were stained with 1.2 mM Coomassie Brilliant Blue and the excess stain was washed away with a mixmre containing 10 % acetic acid and 5 % methanol, after which the gels were measured using a laser densitometer. The catalysis of type I collagen induced by human neutrophil collagenase MMP-8 was measured as percent (%) of type I collagen disintegrated. Both the alpha-hydroxy-isocaproic acid and the alpha-hydroxy-isovaleric acid were found to exert significant inhibition of human MMP-8 already at a concentration level of lOμg/μl. The test result is shown in Fig. 2. Example 6 This example was carried out to test the dose-dependent inhibition of the catalytic activity of human gingival crevicular liquid collagenase (MMP-8 inhibition) by means of alpha-hydroxy acids (for in vivo form of MMP-8, cf. Sorsa et al. , Ann. N.Y. Acad. Sci. 732: 112-131, 1994, Tervahartiala et al. , J. Clin. Periodontol. 23: 68-75, 1996). In the test, human gingival crevicular liquid collagenase (MMP-8, 5 μg, both without and with activation with 1 mM aminophenyl mercuric acetate; cf. Sorsa et al. Ann. N.Y. Acad. Sci. 732: 112- 131 , 1994) was pretreated (at 37 °C for 1 h) with a buffer solution (using TNC buffer solution containing 50 mM Tris-HCl, 0.15 M NaCl, 1 mM CaCl 2 , pH 7.8) and with 1-100 μg/μl alpha-hydroxy-isocaproic acid (d, l-2-hydroxy-4- methyl valeric acid, titrated at pH 7.8) and with alpha-hydroxy isovaleric acid (d, l-2-hydroxy-3-methyl butyric acid, titrated at pH 7.8) and subsequently incubated in TNC buffer solution with 1.5 μM soluble native type I collagen at ambient temperamre (22 °C) for 12 h. Next, the samples were boiled at 100 °C for 5 min in Laemmli buffer solution and analyzed using 8-10 % sodium-dodecyl- sulfate-polyacry lamide gel electrophoresis (cf. Sorsa et al. , Ann. N.Y. Acad. Sci. 732: 112-131, 1994). The SDS-PAGE gels were stained with 1.2 mM Coomassie Brilliant Blue and the stain was washed away with a mixmre containing 10 % acetic acid and 5 % methanol, after which the gels were measured using a laser densitometer. The catalysis of type I collagen induced by human gingival crevicular collagenase MMP-8 was measured as percent (%) of type I collagen disintegrated. Both the alpha-hydroxy-isocaproic acid and the alpha-hydroxy- isovaleric acid were found to exert significant inhibition of human MMP-8 already at a concentration level of lOμg/μl. The test result is shown in Fig. 3. Example 7 This example was carried out to test the reduction/inhibition of the catalytic activity of human fibroblast gelatinase A (72 kD type IV collagenase MMP-2) and of human neutrophil gelatinase B (92 kD type IV collagenase MMP-9) by alpha- hydroxy-isocaproic acid (d,l-2-hydroxy-4-methyl valeric acid, titrated at pH 7.8). In the test, 100 ng purified MMP-2 and 65 ng purified MMP-9 (both without and with activation with 1 mM aminophenyl mercuric acetate) were pretreated (at 37 °C for 1 h) with a buffer solution (using TNC buffer solution containing 50 mM Tris-HCl, 0.15 M NaCl, 1 mM CaCl 2 , pH 7.8) and with 2-80 μg/μl alpha- hydroxy-isocaproic acid (d,l-2-hydroxy-4-methyl valeric acid, titrated at pH 7.8) and subsequently incubated with 1.5 μM 125 I-labelled radioactive type I gelatin (at 37 °C for 1 h), after which the nondisintegrated gelatin substrate was precipitated with 20 % trichloro acetic acid, and the radioactivity of the supernatant phase was measured to obtain an assay of the disintegrated gelatine substrate (cf. Westerlund et al. , J. Dent. Res. , in press, 1996). The alpha- hydroxy-isocaproic acid was found to exert significant inhibition of human gelatinase A (MMP-2) and gelatinase B (MMP-9) at a concentration level of lOμg/μl. The test result is shown in Fig. 4. Example 8 This example was carried out to test the reduction/inhibition of the catalytic activity of human fibroblast gelatinase A (72 kD type IV collagenase MMP-2) by alpha-hydroxy-isovaleric acid (d, l-2-hydroxy-3-methyl butyric acid, titrated at pH 7.8). In the test, 100 ng purified MMP-2 (both without and with activation with 1 mM aminophenyl mercuric acetate) was pretreated (at 37 °C for 1 h) with a buffer solution (using TNC buffer solution containing 50 mM Tris-HCl, 0.15 M NaCl, 1 mM CaCl 2 , pH 7.8) and with 2-80 μg/μl alpha-hydroxy-isovaleric acid (d,l-2-hydroxy-3-methyl butyric acid, titrated at pH 7.8) and subsequently incubated with 1.5 μM 125 I-labelled radioactive type I gelatin (at 37 °C for 1 h), after which the nondisintegrated gelatin substrate was precipitated widi 20 % trichloroacetic acid, and the radioactivity of the supernatant phase was measured to obtain an assay of the disintegrated gelatine substrate (cf. Westerlund et al. , J. Dent. Res., in press, 1996). The alpha-hydroxy-isocaproic acid was found to exert significant inhibition of human gelatinase A (MMP-2) at a concentration level of lOμg/μl. The test result is shown in Fig. 5. Example 9 This example was carried out to test the inhibition of the catalytic activity of cathepsin-G isolated from human neutrophils. In the test, cathepsin-G (10 ng) was pretreated (at 37 °C for 1 h) with TNC buffer solution and with 1.0-100 μg/μl alpha-hydroxy-isocaproic acid (d, l-2-hydroxy-4-methyl valeric acid, titrated at pH 7.8) and subsequently the enzyme solutions were incubated with 1 mM succinyl-alanyl-alanyl-phenylalanyl-paranitroanilide (SAAPNA) peptide substrate at 37 °C for 2 h. The cathepsin-G activities were measured as increase of absorbance at 405 nm wavelength and plotted as either relative changes in absorbance and/or international units of enzyme activity (cf. Tervahartiala et al. , J. Clin. Periodontol. 23: 68-75, 1996). Alpha-hydroxy-isocaproic acid was found to exert effective inhibition of the activity of cathepsin-G at a concentration level 10-50 μg/μl. The test result is shown in Fig. 6. Example 10 This example was carried out to test the inhibition of the catalytic activity of cathepsin-G isolated from human neutrophils. In the test, cathepsin-G (10 ng) was pretreated (at 37 °C for 1 h) with TNC buffer solution and with 1.0-100 μg/μl alpha-hydroxy valeric acid (d, l-2-hydroxy-3-methyl butyric acid, titrated at pH 7.8) and subsequently the enzyme solutions were incubated with 1 mM succinyl-alanyl-alanyl-phenylalanyl-paranitroanilide (SAAPNA) peptide substrate at 37 °C for 2 h. The cathepsin-G activities were measured as increase of absorbance at 405 nm wavelength and plotted as either relative changes in absorbance and/or international units of enzyme activity (cf. Tervahartiala et al. , J. Clin. Periodontol. 23: 68-75, 1996). Alpha-hydroxy-isovaleric acid was found to exert effective inhibition of the activity of cathepsin-G at a concentration level 10-50 μg/μl. The test result is shown in Fig. 7. Example 11 Smdy A. This pan of me example was carried out to test the effect of irrigation/ flushing treatment with 2 % d, l-2-hydroxy-3-methyl butyric acid (HMB) and subsequent rinsing on the health condition of gums and mouth of parodontitis patients. The parodontitis patients participating the study were selected according to the following clinical criteria: deep gingival crevices (depth >4 mm), amount of gingival haemorrhages, visible plaque index, retentive tartar and bone resoφtion detected from x-ray picmres to be related to the deep gingival crevices in parodontitis conditions. 40 parodontitis patients were given flushing treatment with 2 % HMB, while a reference/control group (30 patients) received irrigation/ flushing treatment with Sol. Rotocani, Sol. Polymineroli, and Sol. Maraslavini. After conventional mechanical removal of tartar, the test patients were given irrigation/flushing treatment with 2 % HMB, and subsequently, each patient was given an aliquot of 2 % HMB preparation to be used for mouth rinsing twice a day for 2 weeks; correspondingly, the reference/control group (30 patients) was treated with conventional mechanical removal of tartar and the initial irrigation/ flushing treatment of gingival crevices was performed using Sol. Maraslavini. Sol. Rotokani and Sol Polymineroli preparations, after which the patients were instructed to perform mouth rinsing with water only. Clinical and microbiological smdies were performed before and after the treatment. The microbiological growth tests were carried out on blood agar, chocolate agar and Tsistevits salt agar dishes. When it was necessary to isolate a pure culmre on a differentiating dish, a new culmre was grown on a conventional agar dish, and in unclear cases, the new cultures were grown on differentiating dishes complemented with addi¬ tional biochemical and fermentative tests as required. The results show that the HMB preparation has a two-way action: firstly, the HMB preparation eradicated the pathogenic microbial flora present in the gingival crevices of the parodontitis patients entirely in about 40 % of the cases, and in some cases, the suppression of the microbial flora was better by orders of magnitude as compared with the reference/control group. Secondly, the HMB preparation altered the spectrum of the pre-treatment pathogenic microbial flora of the gingival crevices of the parodontitis patients toward apathogenic direction. The puφose of this test was to assess the effect and function of the HMB prepar¬ ation on the health condition of the gums and die mucosa of the oral cavity over a follow-up period of 2 to 3 months subsequent to a systematic flushing treatment carried out for 2 weeks. It was found that the HMB preparation has an anti- microbial effect lasting 3 months after the treatment. The clinical inflammation indices (gingival haemorrhages and visible plaque indices) characterizing the health condition of the gingival tissue are lowered significantly by virtue of the HMB treatment/prophylaxy. As these symptoms associated with the progress of parodontitis promote the further development of the disease, the HMB preparation may be capable of preventing the progress of gingivitis (and other gingival diseases) and parodontitis. When examined immediately after the completion of the treatment series, 40 % of the patients were found free from pathogenic micro¬ flora, and after 3 months, this figure was still 27.5 %. As compared with the control group, the result was 1.5-fold better. The HMB preparation was capable of shifting the spectrum of the pathogenic microflora toward apathogenic direction. A particularly strong suppressing effect of the HMB preparation was found on streptococcal strains (Streptococcus viridans and mutans). For A-haemolytic streptococci, the HMB preparation was less effective: their number was reduced quantitatively, but viable cocci were still detected. The HMB preparation had also a strong antibacterial efficacy on E. coli. Subjectively, parodontitis patients treated with HMB irrigation experienced a clean and light feeling in their mouths. In conclusion, the tests proved that a 2 % solution of the HMB preparation is suited for active treatment in the irrigation cleaning of deep gingival crevices (depth >4mm) due to parodontitis, followed by extended use of the 2 % solution of the HMB preparation as a mouthwash, particularly as a general prophylaxy against recurrent parodontitis, and in the treatment of and as prophylaxy against recurrence of parodontitis for patients suffering from severe systemic diseases (diabetes, leukemia, arthrites, cancers, vascular diseases and chronic illnesses), as well as general prophylaxy in order to establish a inflammation-resistant condition in the mouth. Test results: 1. Control group, microbiological stams of patients prior to treatment: 30 % having α-haemolytic streptococci 20 % having apathogenic saprophytes 20 % having Escherichia coli 20 % having different types of bacteroid microbes 10 % having haemolytic haemophils (Haemophilus influenzae). Control group, microbiological stams of patients after treatment: 18 % having no growth of micro-organisms 27 % having α-haemolytic streptococci 18 % having growth of Streptococcus viridans 10 % having β-haemolytic streptococci (Streptococcus pyogenes) 10 % having apathogenic saprophytes. 10 % having apathogenic mixed flora. 2. Test group, microbiological stams of patients prior to treatment with HMB: : 46 % having Fam. Streptococeae 15 % having Escherichia coli 12 % having apathogenic mixed flora 10 % having bacteroid microbes 5 % having Haemophilia haemolyticus 5 % having no bacteriological flora 8 % having micrococci. Test group, microbiological status of patients after treatment with a 2 % solution of the HMB preparation: 39 % having no bacteriological flora 18 % having Streptococcus viridans, only a few cells thereof 18 % having apathogenic mixed flora 8 % having α-haemolytic streptococci 8 % having saprophytes, only a few cells 5 % having β-haemolytic streptococci, only a few cells 3 % having micrococci, only a few cells 3 % having treatment uncompleted. Smdy B. This part of the example was carried out to test the efficacy of a 2 % solution of the HMB preparation on the composition of the microbial flora in the toothbrushes of parodontitis patients prior and after the treatment. A microbiological smdy was carried out on samples taken from the gaps between the bristles of patient toothbrushes. Microbes belonging to the group of strepto¬ cocci and the E. coli group were found abundantly prior to the treatment. Treatment with the 2 % solution of the HMB preparation lowered the count of these microbes significantly. As known the interbristle gaps in toothbrushes act as an undisputable retention site for parodontopathogenic and other oral cavity microbes. Furthermore, as toothbrushes are conventionally not washed and dried sterile after use thus forming a moist environment of highly favourable growth, carrier and culmre medium substrate for oral cavity bacteria, the advantageous results obtained herein complement favourably the recommendable procedures of routine washing and disinfection of toothbrushes. To those versed in the art, it is obvious that the different embodiments of the invention are not limited to those described above, but rather, can be varied within the scope and spirit disclosed in the annexed claims.

Claims: Claims: 1. Use of a hydroxy acid containing at least 4 carbons and having either a branched or linear carbon chain, or of a mixmre of said acids, in the manufacture 5 of a preparation having antimicrobial and/or proteinase-activity-inhibiting efficacy . 2. Use as defined in claim 1 of an alpha-hydroxy acid in the form of a compound or compounds incoφorating a branched carbon chain or an aromatic or o other suitable substituent in a product when manufacmring a pharmaceutical product having antimicrobial and/or proteinase-activity-inhibiting efficacy. 3. Use of a hydroxy acid as defined in claim 1 or 2 in product having antimicrobial and/or proteinase-activity-inhibiting efficacy when using an effective 5 amount of 2-hydroxy-3-methyl butyric acid, 2-hydroxy-4-methyl valeric acid, or a mixmre thereof. 4. Use of a hydroxy acid as defined in any foregoing claim in a product intended to exert activity-inhibiting efficacy on matrix metalloproteinases and serine 0 proteinases. 5. Use of a hydroxy acid as defined in any foregoing claim as an antimicrobial or proteinase-activity-inhibiting component in the manufacture of a pharmaceutical product for treatment of otological, oral, gynecological, mucosal, eye, skin and 5 die like objects in animals and humans. 6. Product with antimicrobial and/or proteinase-activity inhibiting efficacy, c h a r a c t e r i z e d by containing, either alone or in combination with other compounds, such a hydroxy acid or a mixmre of such acids that incoφorate at 0 least 4 carbon atoms and may have a branch 1 or linear carbon chain. 7. Product as defined in claim 6, characterized in that said pharmaceutically acceptable product incoφorates a component containing an alpha-hydroxy compound or compounds having a branched carbon chain or an aromatic or other suitable substituent. 8. Product as defined in any of foregoing claims 6-7, characterized in that said product contains an effective amount of 2-hydroxy-3-methyl butyric acid, 2-hydroxy-4-methyl valeric acid or a mixmre thereof. 9. Product as defined in any of foregoing claims, characterized in that said product contains said effective component in either chemically synthesized or biotechnically produced form, or as a mixmre thereof, and that said product is made in pharmaceutically acceptable forms including tablets, capsules, powders, granules, syrups, elixirs and rectal suppositories as well as locally applied preparations including ointments, solutions, dispersions, tinctures, drops and rectal suppositories. 10. Method for treating/preventing animal or human infections, inflammations caused by pathogenic and multiresistant microbes and/or eradicating such microbes from their host, characterized in that said mediod of treatment is based on the use of a hydroxy acid which has at least 4 carbon atoms and may have a branched or linear carbon chain, and that such an acid or a mixmre of such acids is administered as an antimicrobial or proteinase-activity- inhibiting component. 11. Method of treatment as defined in claim 10, characterized in that in said method an alpha-hydroxy acid or a pharmaceutical product containing the same is used as an effective amount for treatment and/or prevention skin, eye, mucosal, gynecological, otological and the like objects, or for eradication of pathogenic and multiresistant bacteria from . sir host. 12. Method of treatment as defined in claim 10 or 11, characterized in that said microbicidally active component in said product is either chemically synthesized or biotechnically produced, or a mixture thereof, and that said component is processed into pharmaceutically acceptable forms including tablets, capsules, powders, granules, syrups, elixirs and rectal suppositories as well as locally applied preparations including ointments, solutions, dispersions, tincmres, drops and rectal suppositories. 13. Method of treatment as defined in any of foregoing claims 10-12, char* acterized in that said method of treatment is based on inhibiting the activity matrix metalloproteinases and/or serine proteinases in diseases or systemic disorders involving pathologically elevated activities and levels of such proteinases and on bringing said activities and levels to normal values in tissues.

Inventors: HIETALA PENTTI, JAARMA MAIRE, SORSA TIMO, VAARA MARTTI, WESTERMARCK HAKON DI, HIETALA, PENTTI, JAARMA, MAIRE, SORSA, TIMO, VAARA, MARTTI, WESTERMARCK, HAKON +DI
Applicants: EXTRACTA LTD, HIETALA PENTTI, JAARMA MAIRE, SORSA TIMO, VAARA MARTTI, WESTERMARCK TUOMAS WALTER & LM, HIETALA, PENTTI, JAARMA, MAIRE, OY EXTRACTA LTD., SORSA, TIMO, VAARA, MARTTI, WESTERMARCK, TUOMAS, WALTER +LM
Application year: 1996
Main classification: A61K31
IPC codes: A61K31